Physician profile
George Newman
NPI 1083616957
$1,367.19
in general payments reported to CMS, 2019-2025
33 companies · $74.00 in 2025
The $74.00 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $178 · 2021: $378 · 2022: $417 · 2023: $164 · 2024: $156 · 2025: $74.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.04 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $157.94 | 2021-2025 | Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $149.29 | 2020-2023 | Jesduvroq |
| Nxstage Medical, INC. | $129.37 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $102.45 | 2020-2023 | Farxiga |
| Alexion Pharmaceuticals, INC. | $97.57 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $95.51 | 2020 | |
| Akebia Therapeutics INC | $75.68 | 2021-2024 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $65.79 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $64.46 | 2023-2024 | |
| Horizon Therapeutics Plc | $59.22 | 2020-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $58.75 | 2022 | |
| Opko Pharmaceuticals, LLC | $52.01 | 2021 | |
| Daiichi Sankyo INC. | $50.45 | 2021-2023 | Injectafer |
| Travere Therapeutics, INC. | $49.18 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $44.98 | 2021-2024 | Acthar |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $39.38 | 2021-2022 | |
| Medtronic, INC. | $21.48 | 2021 | |
| Kyowa Kirin, INC. | $20.70 | 2023 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $17.23 | 2020 | |
| Lilly USA, LLC | $15.75 | 2024 | Jardiance |
13 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.